Britain expects verdict on Pfizer's COVID-19 vaccine before AstraZeneca's - Times
Reuters
Published Oct 28, 2020 23:12
Updated Oct 28, 2020 23:55
(Reuters) - Senior sources in the British government expect that a verdict on whether Pfizer Inc-backed (N:PFE) COVID-19 vaccine works will be available before the results are in on AstraZeneca Plc's (L:AZN) competing vaccine, the Times reported.
Britain believes that the vaccine, which Pfizer is co-developing with Germany's BioNTech SE (F:22UAy), could be ready to distribute before Christmas, the report said.
Pfizer's Chief Executive Albert Bourla has previously said the company could release data on whether or not the vaccine works as early as this month.
The U.S. drugmaker said this week if trials are successful the company expects to file for emergency authorization of the vaccine candidate from U.S. regulators shortly after it has enough safety data in late November.
Britain has agreed supply deals for six vaccine candidates including frontrunners from Pfizer and AstraZeneca.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.